Focal adhesion kinase (FAK) exhibits high expression in various human cancers, making it a focal point for cancer therapy. However, FAK kinase inhibitors, focusing solely on blocking the kinase activity, have shown limited efficacy in clinical trials. Notably, FAK also serves as a scaffold protein in a kinase-independent pathway. To address FAK comprehensively, it is essential to inhibit both the kinase-dependent and kinase-independent pathways. Consequently, we assessed the efficacy of a novel drug, FAK PROTAC, designed to target both kinase and scaffold activities for ovarian cancer therapy. Our evaluation included testing the impact of FAK PROTAC alongside its parent kinase inhibitor (VS-6063) in ovarian cancer cell lines through various cell functional assays, including proliferation, migration, and invasion.
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :